Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2007 | 1 |
2010 | 1 |
2012 | 1 |
2013 | 1 |
2024 | 0 |
Search Results
3 results
Results by year
Filters applied: . Clear all
Page 1
In vitro metabolism of the 5-hydroxytryptamine1B receptor antagonist elzasonan.
Xenobiotica. 2013 Apr;43(4):368-78. doi: 10.3109/00498254.2012.723150. Epub 2012 Oct 3.
Xenobiotica. 2013.
PMID: 23030680
The metabolism of elzasonan has been examined in vitro using hepatic microsomes from human and recombinant heterologously expressed P450 enzymes (rCYP). Metabolism occurs primarily via oxidative N-demethylation to form M4 and oxidation reactions to form elzasonan N- …
The metabolism of elzasonan has been examined in vitro using hepatic microsomes from human and recombinant heterologously expressed P …
Metabolism, pharmacokinetics, and excretion of the 5-hydroxytryptamine1b receptor antagonist elzasonan in humans.
Kamel A, Obach RS, Colizza K, Wang W, O'Connell TN, Coelho RV Jr, Kelley RM, Schildknegt K.
Kamel A, et al.
Drug Metab Dispos. 2010 Nov;38(11):1984-99. doi: 10.1124/dmd.110.034595. Epub 2010 Jul 28.
Drug Metab Dispos. 2010.
PMID: 20668248
The metabolism, pharmacokinetics, and excretion of a potent and selective 5-hydroxytryptamine(1B) receptor antagonist elzasonan have been studied in six healthy male human subjects after oral administration of a single 10-mg dose of [(14)C]elzasonan. Total recovery …
The metabolism, pharmacokinetics, and excretion of a potent and selective 5-hydroxytryptamine(1B) receptor antagonist elzasonan have …
Item in Clipboard
Assessing the onset of antidepressant-induced sexual dysfunction using interactive voice response technology.
Dunn JA, Arakawa R, Greist JH, Clayton AH.
Dunn JA, et al.
J Clin Psychiatry. 2007 Apr;68(4):525-32. doi: 10.4088/jcp.v68n0406.
J Clin Psychiatry. 2007.
PMID: 17474807
Clinical Trial.
METHOD: Sexually active, healthy male volunteers (N = 99; mean age of 31 years) were randomly assigned to 3 weeks of double-blind, parallel-group treatment with paroxetine (20 mg/day); CP-448,187 (3 mg/day); or placebo. Patients completed both paper-and-penci …
METHOD: Sexually active, healthy male volunteers (N = 99; mean age of 31 years) were randomly assigned to 3 weeks of double-blind, parallel- …
Item in Clipboard
Cite
Cite